BRPI0717098B8 - análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação - Google Patents
análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparaçãoInfo
- Publication number
- BRPI0717098B8 BRPI0717098B8 BRPI0717098A BRPI0717098A BRPI0717098B8 BR PI0717098 B8 BRPI0717098 B8 BR PI0717098B8 BR PI0717098 A BRPI0717098 A BR PI0717098A BR PI0717098 A BRPI0717098 A BR PI0717098A BR PI0717098 B8 BRPI0717098 B8 BR PI0717098B8
- Authority
- BR
- Brazil
- Prior art keywords
- insulin analogues
- protease
- preparation
- pharmaceutical composition
- human insulin
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 108091005804 Peptidases Proteins 0.000 title abstract 3
- 239000004365 Protease Substances 0.000 title abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 8
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06121113.2 | 2006-09-22 | ||
| EP06121113 | 2006-09-22 | ||
| EP061211132 | 2006-09-22 | ||
| PCT/EP2007/059990 WO2008034881A1 (en) | 2006-09-22 | 2007-09-20 | Protease resistant insulin analogues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0717098A2 BRPI0717098A2 (pt) | 2013-10-08 |
| BRPI0717098B1 BRPI0717098B1 (pt) | 2018-08-07 |
| BRPI0717098B8 true BRPI0717098B8 (pt) | 2021-05-25 |
Family
ID=38754488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717098A BRPI0717098B8 (pt) | 2006-09-22 | 2007-09-20 | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9018161B2 (OSRAM) |
| EP (2) | EP2074141B1 (OSRAM) |
| JP (2) | JP5864834B2 (OSRAM) |
| KR (2) | KR101729986B1 (OSRAM) |
| CN (1) | CN101541830A (OSRAM) |
| AU (1) | AU2007298919C1 (OSRAM) |
| BR (1) | BRPI0717098B8 (OSRAM) |
| CA (1) | CA2663074A1 (OSRAM) |
| DK (1) | DK2074141T3 (OSRAM) |
| ES (1) | ES2601839T3 (OSRAM) |
| HU (1) | HUE029512T2 (OSRAM) |
| IL (1) | IL197609A (OSRAM) |
| MX (1) | MX2009002999A (OSRAM) |
| NO (1) | NO20091563L (OSRAM) |
| PL (1) | PL2074141T3 (OSRAM) |
| PT (1) | PT2074141T (OSRAM) |
| RU (1) | RU2524150C2 (OSRAM) |
| TW (1) | TW200829600A (OSRAM) |
| WO (1) | WO2008034881A1 (OSRAM) |
| ZA (1) | ZA200901838B (OSRAM) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2505593A1 (en) | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| EP2074141B1 (en) | 2006-09-22 | 2016-08-10 | Novo Nordisk A/S | Protease resistant insulin analogues |
| WO2008132224A2 (en) | 2007-04-30 | 2008-11-06 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| MX2009012789A (es) | 2007-06-01 | 2009-12-10 | Novo Nordisk As | Composiciones farmaceuticas no acuosas estables. |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| CN101677947B (zh) | 2007-06-13 | 2013-07-17 | 诺沃-诺迪斯克有限公司 | 包含胰岛素衍生物的药物制剂 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| CN101970477B (zh) * | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| PT2910570T (pt) * | 2008-03-18 | 2017-01-24 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
| WO2009133099A2 (en) * | 2008-04-28 | 2009-11-05 | Novo Nordisk A/S | Insulin precursors for diabetes treatment |
| DK3228320T3 (da) | 2008-10-17 | 2020-03-09 | Sanofi Aventis Deutschland | Kombination af et insulin og en glp-1-agonist |
| AU2009309623B9 (en) | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| CN102245633A (zh) * | 2008-12-09 | 2011-11-16 | 诺沃—诺迪斯克有限公司 | 新的胰岛素类似物 |
| BRPI1014760B8 (pt) | 2009-06-26 | 2021-05-25 | Novo Nordisk As | preparação compreendendo insulina, nicotinamida e arginina |
| ES2611040T3 (es) * | 2009-06-30 | 2017-05-04 | Novo Nordisk A/S | Derivados de insulina |
| US20120232002A1 (en) * | 2009-07-06 | 2012-09-13 | Sanofi-Aventis Deutschland Gmbh | Slow-acting insulin preparations |
| WO2011033019A1 (en) | 2009-09-16 | 2011-03-24 | Novo Nordisk A/S | Stable non-aqueous liquid pharmaceutical compositions comprising an insulin |
| WO2011051486A2 (en) | 2009-11-02 | 2011-05-05 | Novo Nordisk A/S | Pharmaceutical solution of non covalently bound albumin and acylated insulin |
| PL3417871T3 (pl) | 2009-11-13 | 2021-06-14 | Sanofi-Aventis Deutschland Gmbh | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| BR112012016853A2 (pt) | 2010-01-12 | 2017-10-17 | Novo Nordisk As | "composições farmacêuticas para administração oral de peptídeos de insulina". |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| JP6013330B2 (ja) | 2010-06-23 | 2016-10-25 | ノヴォ ノルディスク アー／エス | 追加のジスルフィド結合を含有するヒトインスリン |
| EP2585484A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| KR20130036290A (ko) | 2010-06-23 | 2013-04-11 | 노보 노르디스크 에이/에스 | 추가 이황화 결합을 함유하는 인슐린 유도체 |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| RU2546520C2 (ru) | 2010-08-30 | 2015-04-10 | Санофи-Авентис Дойчланд Гмбх | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа |
| EP2627670A2 (en) | 2010-10-15 | 2013-08-21 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
| EP2651432A1 (en) | 2010-12-14 | 2013-10-23 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
| JP2014501239A (ja) | 2010-12-14 | 2014-01-20 | ノヴォ ノルディスク アー／エス | インスリン、ニコチンアミドおよびアミノ酸を含む製剤 |
| CN103458873B (zh) | 2011-04-14 | 2016-04-13 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| JP6058646B2 (ja) | 2011-06-15 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 多置換インスリン |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013059213A1 (en) * | 2011-10-18 | 2013-04-25 | Amidebio, Llc | Chemically and thermodynamically stable insulin analogues and improved methods for their production |
| BR112014025132A2 (pt) | 2012-04-11 | 2017-07-11 | Novo Nordisk As | formulações de insulina |
| WO2013186138A1 (en) | 2012-06-14 | 2013-12-19 | Novo Nordisk A/S | Preparation comprising insulin, nicotinamide and arginine |
| EP2908846A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk A/S | Fatty acid acylated d-amino acids for oral peptide delivery |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| EP2981310B1 (en) | 2013-04-05 | 2017-07-12 | Novo Nordisk A/S | Dose logging device for a drug delivery device |
| WO2014172488A2 (en) | 2013-04-17 | 2014-10-23 | AmideBio LLC | Chemically and thermodynamically stable insulin analogues and improved methods for their production |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| PT2991671T (pt) | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
| PT3055325T (pt) | 2013-10-07 | 2018-04-06 | Novo Nordisk As | Novo derivado de um análogo de insulina |
| SG11201604708VA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| AU2015205620A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| ES2949095T3 (es) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
| US20180000742A1 (en) * | 2015-01-29 | 2018-01-04 | Novo Nordisk A/S | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| UY36870A (es) * | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| EP3487876A4 (en) | 2016-07-22 | 2020-02-19 | University of Utah Research Foundation | INSULIN ANALOGS |
| CN110546161B (zh) | 2016-09-23 | 2024-01-26 | 韩美药品股份有限公司 | 对胰岛素受体具有降低的结合力的胰岛素类似物及其用途 |
| CN109891237B (zh) * | 2016-10-24 | 2022-08-23 | 诺和诺德股份有限公司 | 胰岛素制剂的生物测定法 |
| JP7076442B2 (ja) | 2016-11-07 | 2022-05-27 | ノヴォ ノルディスク アー／エス | Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用 |
| EP3541362B1 (en) | 2016-11-15 | 2025-11-05 | Klaria Pharma Holding AB | Alginate film comprising a triptan |
| PT3554534T (pt) | 2016-12-16 | 2021-11-05 | Novo Nordisk As | Composições farmacêuticas contendo insulina |
| EP3604328A4 (en) * | 2017-03-23 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY FOR THE INSULIN RECEPTOR AND USE OF IT |
| EP3606560A2 (en) | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| AU2018317810A1 (en) | 2017-08-17 | 2020-03-19 | Novo Nordisk A/S | Novel acylated insulin analogues and uses thereof |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR102646845B1 (ko) | 2018-08-08 | 2024-03-14 | 주식회사 대웅제약 | 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법 |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| EP3852873A1 (en) | 2018-09-19 | 2021-07-28 | Ziylo Ltd | Glucose sensitive insulins and uses thereof |
| CN112839681A (zh) | 2018-10-10 | 2021-05-25 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物及其医学用途 |
| BR112021011050A2 (pt) | 2018-12-11 | 2021-08-31 | Sanofi | Ligante peptídico |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
| EP4073096A1 (en) | 2019-12-10 | 2022-10-19 | Sanofi | A method of forming a conjugate of a sulfonamide and a polypeptide |
| PE20230832A1 (es) | 2020-05-15 | 2023-05-19 | Lilly Co Eli | Compuestos de insulina acilada de accion temporal prolongada |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| WO2023144240A1 (en) | 2022-01-26 | 2023-08-03 | Novo Nordisk Research Centre Oxford Limited | Glucose sensitive insulin derivatives and uses thereof |
| CN115716877B (zh) * | 2022-07-04 | 2023-09-01 | 北京惠之衡生物科技有限公司 | 一种表达glp-1和胰岛素缀合物多肽的重组工程菌 |
| WO2024194897A1 (en) * | 2023-03-22 | 2024-09-26 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | A glycation resistant insulin polypeptide and a method of preparing the same thereof |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2832685A (en) | 1952-05-24 | 1958-04-29 | Crest Foods Co Inc | Solubilization of milk proteins |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3719655A (en) | 1969-12-05 | 1973-03-06 | Lilly Co Eli | Process for the crystallization of the ammonium and alkali metal salts in insulin |
| US3950517A (en) | 1970-05-08 | 1976-04-13 | National Research Development Corporation | Insulin derivatives |
| US3869437A (en) | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4033941A (en) | 1975-12-17 | 1977-07-05 | Eli Lilly And Company | Process for purifying glucagon |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
| US4546082A (en) | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| DK463887D0 (da) | 1987-09-07 | 1987-09-07 | Novo Industri As | Gaerleader |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| DK336188D0 (da) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | Propeptider |
| KR900701842A (ko) | 1988-07-20 | 1990-12-04 | 헨리 브뢰늄 | 인간 인슐린 동족체와 그를 포함하는 제제 |
| WO1990007522A1 (en) | 1988-12-23 | 1990-07-12 | Novo Nordisk A/S | Human insulin analogues |
| US5716927A (en) | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
| DE3844211A1 (de) | 1988-12-29 | 1990-07-05 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| DK105489D0 (da) | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| AU631868B2 (en) | 1989-04-20 | 1992-12-10 | Mount Sinai School Of Medicine Of The City University Of New York, The | Hepatospecific insulin analogues |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| KR930001305B1 (ko) | 1989-10-19 | 1993-02-25 | 니뽕 유우시 가부시끼가이샤 | 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type) |
| US5179189A (en) | 1990-01-19 | 1993-01-12 | Nova Pharmaceutical Corporation | Fatty acid terminated polyanhydrides |
| DK45590D0 (OSRAM) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| DK158390D0 (da) | 1990-07-02 | 1990-07-02 | Novo Nordisk As | Nye peptider |
| AU8091091A (en) | 1990-07-26 | 1992-02-18 | University Of Iowa Research Foundation, The | Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| US5336782A (en) | 1991-04-24 | 1994-08-09 | Kuraray Co., Ltd. | Long chain carboxylic acid imide ester |
| AU739601B2 (en) | 1991-07-03 | 2001-10-18 | Meditech Research Limited | Use of hyaluronan in gene therapy |
| TW224471B (OSRAM) | 1991-11-26 | 1994-06-01 | Lilly Co Eli | |
| AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| DE122004000035I2 (de) | 1993-09-17 | 2009-08-06 | Novo Nordisk As | Acyliertes insulin |
| GB9323588D0 (en) | 1993-11-16 | 1994-01-05 | Cortecs Ltd | Hydrophobic preparation |
| AU1272295A (en) | 1993-12-17 | 1995-07-03 | Novo Nordisk A/S | Proinsulin-like compounds |
| JPH10501519A (ja) | 1994-03-07 | 1998-02-10 | インヘイル・セラピューティック・システムズ | インシュリンを肺に送給できる方法および組成物 |
| US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| IL114160A (en) | 1994-06-17 | 2006-12-31 | Novo Nordisk As | Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| KR0150565B1 (ko) | 1995-02-15 | 1998-08-17 | 김정재 | 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법 |
| AU720966B2 (en) | 1995-03-17 | 2000-06-22 | Novo Nordisk A/S | Insulin derivatives |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US20030104981A1 (en) | 1995-11-03 | 2003-06-05 | Jelena Mandic | Human insulin analogues |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| AU3255397A (en) | 1996-07-05 | 1998-02-02 | Novo Nordisk A/S | Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides |
| JP3300368B2 (ja) | 1996-07-11 | 2002-07-08 | ノボ ノルディスク アクティーゼルスカブ | 選択的アシル化方法 |
| EP0821006B1 (de) | 1996-07-26 | 2004-04-21 | Aventis Pharma Deutschland GmbH | Insulinderivate mit erhöhter Zinkbindung |
| AU5549998A (en) | 1997-01-24 | 1998-08-18 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US5898067A (en) | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| UA69393C2 (uk) | 1997-10-24 | 2004-09-15 | Ново Нордіск А/С | Водорозчинний агрегат похідної інсуліну |
| BR9813111A (pt) | 1997-10-24 | 2000-08-15 | Lilly Co Eli | Composições de insulina insolúveis |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CA2309955A1 (en) | 1997-11-12 | 1999-05-20 | Alza Corporation | Method for decreasing self-association of polypeptides |
| US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| AU8029798A (en) | 1998-06-12 | 2000-01-05 | Deutsches Wollforschungsinstitut | Insulin analogue |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| DK1107743T3 (da) | 1998-08-25 | 2007-10-22 | Advanced Inhalation Res Inc | Stabile, spraytörrede proteinformuleringer |
| TW570805B (en) | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
| US7030083B2 (en) | 1998-09-09 | 2006-04-18 | University Of Washington | Treatment of eclampsia and preeclampsia |
| EP1121144B1 (en) | 1998-10-16 | 2002-06-05 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| US6660715B2 (en) | 1998-11-19 | 2003-12-09 | Massachusetts Institute Of Technology | Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery |
| EP1146896B1 (en) | 1999-01-26 | 2002-07-24 | Eli Lilly And Company | Monodisperse hexameric acylated insulin analog formulations |
| WO2000061178A1 (en) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| AU4450700A (en) | 1999-04-27 | 2000-11-10 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| JP2003518917A (ja) | 1999-05-19 | 2003-06-17 | ゼンコー | 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質 |
| US6746853B1 (en) | 1999-05-19 | 2004-06-08 | Xencor, Inc. | Proteins with insulin-like activity useful in the treatment of diabetes |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| CN1141974C (zh) | 2000-06-07 | 2004-03-17 | 张昊 | 结肠定位释放的口服生物制剂 |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| CN1160122C (zh) | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
| AP1763A (en) | 2001-05-21 | 2007-08-02 | Nektar Therapeutics | Pulmonary administration of chemically modified insulin |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| JP2004537580A (ja) | 2001-08-10 | 2004-12-16 | エピックス メディカル， インコーポレイテッド | 延長された循環半減期を有するポリペプチド結合体 |
| ATE446971T1 (de) | 2001-09-07 | 2009-11-15 | Biocon Ltd | Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US7030082B2 (en) | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| AU2002349295A1 (en) | 2001-12-02 | 2003-06-17 | Novo Nordisk A/S | Glucose dependant release of insulin from glucose sensing insulin derivatives |
| WO2003047493A2 (en) | 2001-12-03 | 2003-06-12 | Dor Biopharma Inc. | Stabilized reverse micelle compositions and uses thereof |
| WO2003050276A1 (en) | 2001-12-05 | 2003-06-19 | Dow Global Technologies Inc. | Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications |
| EP1545460A4 (en) | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
| EP1506003A1 (en) | 2002-05-07 | 2005-02-16 | Novo Nordisk A/S | Soluble formulations comprising insulin aspart and insulin detemir |
| EP1506230B1 (en) | 2002-05-07 | 2011-01-19 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| AU2003236521A1 (en) | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| CN1165549C (zh) | 2002-06-15 | 2004-09-08 | 江苏万邦生化医药股份有限公司 | 胰岛素的纯化方法 |
| WO2004105790A1 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| WO2005005477A2 (en) | 2003-07-11 | 2005-01-20 | Novo Nordisk A/S | Stabilised insulin compositions |
| AU2004261319B2 (en) | 2003-07-25 | 2010-12-23 | Conjuchem Biotechnologies Inc. | Long lasting insulin derivatives and methods thereof |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| WO2005016312A1 (en) | 2003-08-13 | 2005-02-24 | Nobex Corporation | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| EP1687428A1 (en) | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| CN102784386A (zh) | 2003-11-20 | 2012-11-21 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| WO2005058961A2 (en) | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
| DE10358387A1 (de) | 2003-12-13 | 2005-07-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung |
| US7625865B2 (en) | 2004-03-26 | 2009-12-01 | Universita Degli Studi Di Parma | Insulin highly respirable microparticles |
| CN101151048A (zh) | 2004-05-10 | 2008-03-26 | 纳斯泰克制药公司 | 增强甲状旁腺激素粘膜递送的组合物和方法 |
| BRPI0513508B1 (pt) | 2004-07-19 | 2021-06-01 | Biocon Limited | Conjugados de insulina-oligômero, formulações e usos desses |
| BR122019022692B1 (pt) | 2004-08-23 | 2023-01-10 | Mannkind Corporation | Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo |
| CA2587601C (en) * | 2004-12-03 | 2017-11-07 | Rhode Island Hospital | Diagnosis and treatment of alzheimer's disease |
| US20090036353A1 (en) | 2005-01-27 | 2009-02-05 | Novo Nordisk A/S | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers |
| EP2256130B1 (en) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| EP1846447B1 (en) | 2005-02-02 | 2013-08-21 | Novo Nordisk A/S | Insulin derivatives |
| WO2006097521A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| WO2007006320A1 (en) | 2005-07-12 | 2007-01-18 | Sherine Hassan Abbas Helmy | Drinkable oral insulin liquid and capsules |
| WO2007041481A1 (en) | 2005-09-29 | 2007-04-12 | Biodel, Inc. | Rapid acting and prolonged acting insulin preparations |
| CA2626357A1 (en) | 2005-10-20 | 2007-04-26 | Nastech Pharmaceutical Company Inc. | Intranasal administration of rapid acting insulin |
| EP2505593A1 (en) | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| WO2007081824A2 (en) * | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| JP2009527526A (ja) | 2006-02-21 | 2009-07-30 | ノボ・ノルデイスク・エー／エス | 単鎖インスリンのアナログとその製薬的製剤 |
| DE602007009496D1 (de) | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
| EP1996223A1 (en) | 2006-03-13 | 2008-12-03 | Novo Nordisk A/S | Acylated single chain insulin |
| MX2008014061A (es) | 2006-05-09 | 2008-11-14 | Novo Nordisk As | Derivado de insulina. |
| EP2024390B1 (en) | 2006-05-09 | 2015-08-19 | Novo Nordisk A/S | Insulin derivative |
| JP5550338B2 (ja) * | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | ペグ化持続型インスリン |
| EP2074141B1 (en) | 2006-09-22 | 2016-08-10 | Novo Nordisk A/S | Protease resistant insulin analogues |
| EP2514412A1 (en) | 2007-04-30 | 2012-10-24 | Novo Nordisk A/S | Highly Concentrated Insulin Solutions and Compositions |
| MX2009012789A (es) | 2007-06-01 | 2009-12-10 | Novo Nordisk As | Composiciones farmaceuticas no acuosas estables. |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| CN101743252A (zh) | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
| EP2017288A1 (en) | 2007-07-16 | 2009-01-21 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
| US9150633B2 (en) | 2007-08-15 | 2015-10-06 | Novo Nordisk A/S | Insulin analogues with an acyl and alkylene glycol moiety |
| EP2178910B1 (en) | 2007-08-15 | 2014-10-08 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| CN101970477B (zh) | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| PT2910570T (pt) | 2008-03-18 | 2017-01-24 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
-
2007
- 2007-09-20 EP EP07820423.7A patent/EP2074141B1/en not_active Revoked
- 2007-09-20 CN CNA2007800431301A patent/CN101541830A/zh active Pending
- 2007-09-20 HU HUE07820423A patent/HUE029512T2/en unknown
- 2007-09-20 CA CA002663074A patent/CA2663074A1/en not_active Withdrawn
- 2007-09-20 ES ES07820423.7T patent/ES2601839T3/es active Active
- 2007-09-20 US US12/442,190 patent/US9018161B2/en active Active
- 2007-09-20 KR KR1020157005461A patent/KR101729986B1/ko not_active Expired - Fee Related
- 2007-09-20 PL PL07820423T patent/PL2074141T3/pl unknown
- 2007-09-20 PT PT78204237T patent/PT2074141T/pt unknown
- 2007-09-20 EP EP11173251A patent/EP2404934A1/en not_active Withdrawn
- 2007-09-20 RU RU2009114324/10A patent/RU2524150C2/ru not_active IP Right Cessation
- 2007-09-20 DK DK07820423.7T patent/DK2074141T3/en active
- 2007-09-20 BR BRPI0717098A patent/BRPI0717098B8/pt not_active IP Right Cessation
- 2007-09-20 WO PCT/EP2007/059990 patent/WO2008034881A1/en not_active Ceased
- 2007-09-20 AU AU2007298919A patent/AU2007298919C1/en not_active Ceased
- 2007-09-20 MX MX2009002999A patent/MX2009002999A/es active IP Right Grant
- 2007-09-20 KR KR1020097005790A patent/KR101699370B1/ko not_active Expired - Fee Related
- 2007-09-20 JP JP2009528727A patent/JP5864834B2/ja active Active
- 2007-09-21 TW TW096135252A patent/TW200829600A/zh unknown
-
2009
- 2009-03-16 ZA ZA2009/01838A patent/ZA200901838B/en unknown
- 2009-03-16 IL IL197609A patent/IL197609A/en active IP Right Grant
- 2009-04-20 NO NO20091563A patent/NO20091563L/no not_active Application Discontinuation
-
2014
- 2014-01-24 JP JP2014011829A patent/JP2014129355A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW200829600A (en) | 2008-07-16 |
| BRPI0717098B1 (pt) | 2018-08-07 |
| MX2009002999A (es) | 2009-04-01 |
| AU2007298919C1 (en) | 2014-02-06 |
| KR101699370B1 (ko) | 2017-02-14 |
| PT2074141T (pt) | 2016-11-10 |
| HUE029512T2 (en) | 2017-03-28 |
| IL197609A (en) | 2017-04-30 |
| EP2074141A1 (en) | 2009-07-01 |
| JP2014129355A (ja) | 2014-07-10 |
| AU2007298919A1 (en) | 2008-03-27 |
| US20100009898A1 (en) | 2010-01-14 |
| ZA200901838B (en) | 2010-02-24 |
| CA2663074A1 (en) | 2008-03-27 |
| RU2524150C2 (ru) | 2014-07-27 |
| DK2074141T3 (en) | 2016-11-28 |
| KR20150031494A (ko) | 2015-03-24 |
| EP2074141B1 (en) | 2016-08-10 |
| CN101541830A (zh) | 2009-09-23 |
| NO20091563L (no) | 2009-04-20 |
| KR20090071561A (ko) | 2009-07-01 |
| WO2008034881A1 (en) | 2008-03-27 |
| US9018161B2 (en) | 2015-04-28 |
| RU2009114324A (ru) | 2010-10-27 |
| EP2404934A1 (en) | 2012-01-11 |
| IL197609A0 (en) | 2011-08-01 |
| BRPI0717098A2 (pt) | 2013-10-08 |
| KR101729986B1 (ko) | 2017-04-25 |
| PL2074141T3 (pl) | 2017-02-28 |
| JP5864834B2 (ja) | 2016-02-17 |
| JP2010504087A (ja) | 2010-02-12 |
| ES2601839T3 (es) | 2017-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0717098B8 (pt) | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| BRPI0511421A (pt) | composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
| BR0317458A (pt) | EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BRPI0413276B8 (pt) | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica | |
| BRPI0511703B8 (pt) | composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição | |
| BR0214986A (pt) | S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BR0307576A (pt) | Compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças associadas com o dpp iv; e uso de compostos | |
| BRPI0910461B8 (pt) | hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso | |
| BRPI0408490A (pt) | composições que compreendem ácidos graxos e aminoácidos | |
| BRPI0517701A (pt) | uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus | |
| BR0215029A (pt) | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus | |
| BRPI0820622A2 (pt) | Compostos derivados de aminotiazol, processo para a sua preparação, composição farmacêutica que os compreende, uso dos mesmos e métodos para o tratamento e/ou profilaxia de diabetes e outras enfermidades | |
| BRPI0619605A8 (pt) | moléculas de anticorpos contra amilóide beta4 com glicosilação na região variável, uso das mesmas, método de preparação de uma molécula de anticorpo, composição e kit | |
| BRPI0915592A2 (pt) | composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii | |
| BRPI0606930A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente | |
| BRPI0820203A2 (pt) | Compostos de pirrdina, processo para a sua preparação, composição farmacêutica que os compreende, uso de composto e método para o tratamento e/ou profilaxia de diabetes mellitus do tipo ii e outras enfermidades | |
| BRPI0608840B8 (pt) | composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação | |
| BR0116169A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto. | |
| BRPI0805826B8 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
| BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
| BRPI0715853B8 (pt) | uso de polióis contendo pelo menos dois grupos hidróxi para estabilizar formas polimorfas da rifaximina, rifaximina beta, suas preparações medicinais, seus microgrânulos e seu processo de preparação | |
| BRPI0809680A2 (pt) | Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2793 DE 16-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |